Her-2/neu and Topoisomerase iiα in Breast Cancer

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2003-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1023/A:1023077507295
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Amplification of HSD17B1 and ERBB2 in primary breast cancer

  2003cited by this paper
• HER-2/neu and topoisomerase IIalpha--simultaneous drug targets in cancer.

  2003cited by this paper
• Comparison of Topoisomerase-IIα Gene Status between Primary Breast Cancer and Corresponding Distant Metastatic Sites

  2003cited by this paper
• HER2/Neu: mechanisms of dimerization/oligomerization

  2002cited by this paper
• Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer.

  2002cited by this paper
• New insights into testicular germ cell tumorigenesis from gene expression profiling.

  2002cited by this paper
• Evaluation of HER-2/NEU Protein Expression in Breast Cancer by Immunohistochemistry: An Interlaboratory Study Assessing the Reproducibility of HER-2/NEU Testing

  2002cited by this paper
• Culprit and victim -- DNA topoisomerase II.

  2002cited by this paper
• Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array

  2002cited by this paper
• Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

  2002cited by this paper
• HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.

  2002cited by this paper
• Impact of DNA amplification on gene expression patterns in breast cancer.

  2002cited by this paper
• Amplification and expression of genes from the 17q11 approximately q12 amplicon in breast cancer cells.

  2002cited by this paper
• Targets of gene amplification and overexpression at 17q in gastric cancer.

  2002cited by this paper
• Amplification and expression of genes from the 17q11∼q12 amplicon in breast cancer cells

  2002cited by this paper
• Predictive Factors for Response to Chemotherapy in Advanced Breast Cancer

  2002cited by this paper
• The peroxisome proliferator-activated receptor gamma is an inhibitor of ErbBs activity in human breast cancer cells.

  2001cited by this paper
• The basic biology of HER2.

  2001cited by this paper
• Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases

  2001cited by this paper
• Amplification of Growth Regulatory Genes in Intraductal Breast Cancer Is Associated with Higher Nuclear Grade but Not with the Progression to Invasiveness

  2001cited by this paper
• HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression

  2001cited by this paper
• HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.

  2001cited by this paper
• Molecular targets for breast cancer therapy and prevention

  2001influential reference
• When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer.

  2001influential reference
• Improving the efficacy of antibody-based cancer therapies

  2001influential reference
• Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.

  2001cited by this paper
• New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays.

  2001cited by this paper
• Untangling the ErbB signalling network

  2001influential reference
• Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect.

  2001cited by this paper
• Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients.

  2001cited by this paper
• Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001influential reference
• Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

  2001cited by this paper
• Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells.

  2000influential reference
• Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction.

  2000cited by this paper
• Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.

  2000cited by this paper
• Overexpression of ErbB2 in cancer and ErbB2-targeting strategies

  2000cited by this paper
• Molecular mechanisms underlying ErbB2/HER2 action in breast cancer

  2000influential reference
• HER2/Neu: mechanisms of dimerization/oligomerization

  2000cited by this paper
• Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors.

  2000cited by this paper
• Effects of HER-2/neu on chemosensitivity of tumor cells.

  2000cited by this paper
• Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.

  2000cited by this paper
• Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.

  2000cited by this paper
• DNA topoisomerase IIβ and neural development

  2000cited by this paper
• Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer.

  1999cited by this paper
• Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer.

  1999cited by this paper
• Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer.

  1999cited by this paper
• Using HER2 to choose chemotherapy in breast cancer: is it ready for the clinic?

  1999cited by this paper
• The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.

  1999cited by this paper
• Concomitant gastrin and ERBB2 gene amplifications at 17q12–q21 in the intestinal type of gastric cancer

  1999cited by this paper
• Characterization of topoisomerase IIα gene amplification and deletion in breast cancer

  1999cited by this paper
• Tissue microarrays for gene amplification surveys in many different tumor types.

  1999cited by this paper
• Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  1999cited by this paper
• Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells.

  1999cited by this paper
• HER-2/neu (c-erb-B2) gene and protein in breast cancer.

  1999cited by this paper
• Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

  1999cited by this paper
• Correlation between p53, c‐erbB‐2, and topoisomerase IIα expression, DNA ploidy, hormonal receptor status and proliferation in 356 node‐negative breast carcinomas: prognostic implications

  1999cited by this paper
• Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.

  1999cited by this paper
• p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer.

  1998cited by this paper
• A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer.

  1998cited by this paper
• Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.

  1998cited by this paper
• erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

  1998cited by this paper
• erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.

  1998cited by this paper
• Physiological regulation of eukaryotic topoisomerase II.

  1998cited by this paper
• Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

  1998cited by this paper
• The 1998 St. Gallen's Consensus Conference: an assessment.

  1998cited by this paper
• p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.

  1998cited by this paper
• No significant predictive value of c‐ erbB‐2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer

  1998cited by this paper
• Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status?

  1998cited by this paper
• HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

  1997cited by this paper
• Cell Cycle–coupled Relocation of Types I and II Topoisomerases and Modulation of Catalytic Enzyme Activities

  1997cited by this paper
• The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

  1997influential reference
• Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer.

  1997cited by this paper
• Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4.

  1996cited by this paper
• Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel.

  1996cited by this paper
• Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.

  1996cited by this paper
• Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.

  1996influential reference
• Two distinct amplified regions at 17q11-q21 involved in human primary breast cancer.

  1996cited by this paper
• Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide.

  1996cited by this paper
• Differential expression of the topoisomerase II alpha and beta genes in human breast cancers.

  1996cited by this paper
• Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer.

  1996cited by this paper
• Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide.

  1996cited by this paper
• Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene.

  1996cited by this paper
• Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA.

  1993cited by this paper
• Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity.

  1993cited by this paper
• Co-amplification of erbB2, topoisomerase II α and retinoic acid receptor α genes in breast cancer and allelic loss at topoisomerase I on chromosome 20

  1993cited by this paper
• HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.

  1992influential reference
• Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

  1992cited by this paper
• Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene

  1987cited by this paper
• Identification of the genetic locus for the structural gene and a new regulatory gene for the synthesis of repressible alkaline phosphatase in Saccharomyces cerevisiae

  1982cited by this paper

• Real-world data of subcutaneous trastuzumab and intravenous pertuzumab as neoadjuvant therapy for localized HER2+ breast cancer in Panama

  2021cites this paper
• LncRNA XIST promotes chemoresistance of breast cancer cells to doxorubicin by sponging miR‐200c‐3p to upregulate ANLN

  2020cites this paper
• Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101.

  2019cites this paper
• Expression of HER2 and topoisomerase II &agr; in urinary bladder transitional and squamous cell carcinoma

  2017influential citation
• Plant derived anti-cancerous secondary metabolites as multipronged inhibitor of COX, Topo, and aromatase: molecular modeling and dynamics simulation analyses

  2017cites this paper
• A human Fab exclusively binding to the extracellular domain of LMP2A.

  2017cites this paper
• DNA topoisomerase‐directed anticancerous alkaloids: ADMET‐based screening, molecular docking, and dynamics simulation

  2016cites this paper
• Molecular dynamics simulated validation of anti-cancerous alkaloids as Topo IIβ inhibitors screened by QSAR, pharmacophore and molecular docking approaches

  2015cites this paper
• Nanobiotechnological Approaches to Overcome Drug Resistance in Breast Cancer.

  2015cites this paper
• TOP2A Amplification and Overexpression in Hepatocellular Carcinoma Tissues

  2015cites this paper
• Over-expression of TRIM37 promotes cell migration and metastasis in hepatocellular carcinoma by activating Wnt/β-catenin signaling.

  2015cites this paper
• The role of HER-2 in Breast Cancer.

  2014cites this paper
• AHuman Recombinant Autoantibody-Based Immunotoxin Specific for the Fetal Acetylcholine Receptor Inhibits Rhabdomyosarcoma Growth In Vitro and in aMurine

  2014cites this paper
• MicroRNA-484 is more highly expressed in serum of early breast cancer patients compared to healthy volunteers

  2014cites this paper
• Predictive factors determining neoadjuvant chemotherapy outcomes in breast cancer - a single center experience.

  2013cites this paper
• BRCA 1 AND TOP 2 A GENE AMPLIFICATION AND PROTEIN EXPRESSION IN FOUR MOLECULAR SUBTYPES OF BREAST CANCER

  2013cites this paper
• Korelacija između proteinske i genske ekspresije HER-2 i topoizomeraze 2a kod infiltrativnog duktalnog karcinoma dojke

  2013cites this paper
• Gene amplification: mechanisms and involvement in cancer

  2013cites this paper
• Therapeutic strategies in male breast cancer: clinical implications of chromosome 17 gene alterations and molecular subtypes.

  2013cites this paper
• A Fourteen Gene GBM Prognostic Signature Identifies Association of Immune Response Pathway and Mesenchymal Subtype with High Risk Group

  2013cites this paper
• BRCA1 AND TOP2A GENE AMPLIFICATION AND PROTEIN EXPRESSION IN FOUR MOLECULAR SUBTYPES OF BREAST CANCER

  2013cites this paper
• Multidrug Resistence and Breast Cancer

  2012cites this paper
• Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor

  2012cites this paper
• Therapeutic Discovery A Human Fab-Based Immunoconjugate Speci fi c for the LMP 1 Extracellular Domain Inhibits Nasopharyngeal Carcinoma Growth In Vitro and In Vivo

  2012cites this paper
• Prognostic Value of TOP2A Gene Amplification and Chromosome 17 Polysomy in Early Breast Cancer

  2012cites this paper
• Investigation of CD28 Gene Polymorphisms in Patients with Sporadic Breast Cancer in a Chinese Han Population in Northeast China

  2012cites this paper
• Multiplication of Chromosome 17 Centromere Is Associated with Prognosis in Patients with Invasive Breast Cancers Exhibiting Normal HER2 and TOP2A Status

  2012cites this paper
• Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.

  2011cites this paper
• Detection of HER2 and Topo 2 in breast cancers: comparison between MLPA and FISH approaches

  2011cites this paper
• GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays

  2011cites this paper
• A Human Fab-Based Immunoconjugate Specific for the LMP1 Extracellular Domain Inhibits Nasopharyngeal Carcinoma Growth In Vitro and In Vivo

  2011cites this paper
• Tumor Topoisomerase II Alpha Status and Response to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer

  2011cites this paper
• Tumour Topoisomerase II Alpha Protein Expression and Outcome After Adjuvant Dose-Dense Anthracycline-Based Chemotherapy

  2011cites this paper
• A human epidermal growth factor receptor 2 expression-based approach to neoadjuvant chemotherapy for operable breast cancer.

  2010cites this paper
• Topoisomerase IIα expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer

  2010cites this paper
• Adjuvant chemotherapy in early-stage breast cancer: what, when, and for whom?

  2010cites this paper
• A Human Recombinant Autoantibody-Based Immunotoxin Specific for the Fetal Acetylcholine Receptor Inhibits Rhabdomyosarcoma Growth In Vitro and in a Murine Transplantation Model

  2010cites this paper
• Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study

  2009cites this paper
• Solamargine induces apoptosis and enhances susceptibility to trastuzumab and epirubicin in breast cancer cells with low or high expression levels of HER2/neu.

  2009cites this paper
• Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response.

  2009cites this paper
• The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.

  2009cites this paper
• Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts

  2008cites this paper
• HER2 und Topoisomerase IIα-Expression und Amplifikation des Mamma-Karzinoms - Einfluss auf das Ansprechen anthrazyklinhaltiger Chemotherapie sowie auf die Präsenz Isolierter Tumorzellen im Knochenmark (ITZ-KM)

  2008cites this paper
• Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.

  2008cites this paper
• Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.

  2008cites this paper
• Her2 Expression and Response of Breast Cancer to Adjuvant Chemotherapy

  2008cites this paper
• Facts and controversies in the use of trastuzumab in the adjuvant setting

  2008cites this paper
• Therapy Insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects

  2008cites this paper
• Regulatory Issues in the Co-Development of Oncology Drugs and Proteomic Tests: An Overview

  2008cites this paper
• Phenotypic and Genetic Characterization of Circulating Tumor Cells by Combining Immunomagnetic Selection and FICTION Techniques

  2008influential citation
• Chromogenic and fluorescent in situ hybridization in breast cancer.

  2007cites this paper
• Topoisomerase II alpha expression in testicular germ cell tumors.

  2007cites this paper
• Chemosensitivity in Breast Cancer

  2007cites this paper
• Downregulation of HER2/neu receptor by solamargine enhances anticancer drug-mediated cytotoxicity in breast cancer cells with high-expressing HER2/neu

  2007cites this paper
• 11 Regulatory Aspects of the Oncology Drug Diagnostics Co-Development Process by Proteomics Approach

  2007cites this paper
• Effect of structural modification at the 4, 3′, and 2′ positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells

  2007cites this paper
• Does Polysomy of Chromosome 17 Have a Role in ERBB2 and Topoisomerase IIα Expression?

  2007cites this paper
• The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours.

  2007cites this paper
• Does polysomy of chromosome 17 have a role in ERBB2 and topoisomerase IIalpha expression? Gene, mRNA and protein expression: a comprehensive analysis.

  2007cites this paper
• Neutral dimeric copper–sparfloxacin conjugate having butterfly motif with antiproliferative effects against hormone independent BT20 breast cancer cell line

  2007cites this paper
• Adult Urology Topoisomerase II Alpha Expression in Testicular Germ Cell Tumors

  2007cites this paper
• Oncogenes and Tumor Suppressor Genes in Therapeutic Resistance

  2006cites this paper
• Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.

  2006cites this paper
• TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer

  2006cites this paper
• Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.

  2006cites this paper
• Association between Immunohistochemical Expression of Topoisomerase IIα, Her2 and Hormone Receptors and Response to Primary Chemotherapy in Breast Cancer

  2006cites this paper
• Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes.

  2006cites this paper
• Topoisomerase IIα Gene Amplification and Response to Anthracycline-Containing Adjuvant Chemotherapy in Breast Cancer

  2006cites this paper
• Predictive Value of c--erb-B2 for Endocrine Therapy and Chemotherapy in Breast Cancer

  2006cites this paper
• BIOLOGICAL THERAPIES FOR BREAST CANCER

  2006cites this paper
• Assays for Gene Amplification

  2006cites this paper
• Topoisomerase IIα in Wilms’ tumour: gene alterations and immunoexpression

  2006cites this paper
• Molecular Dissection of 17q12 Amplicon in Upper Gastrointestinal Adenocarcinomas

  2006cites this paper
• Novel patterns of genome rearrangement and their association with survival in breast cancer.

  2006influential citation
• HER-2 status determination in breast carcinomas. A practical approach.

  2006cites this paper
• Topoisomerase II alpha expression and cytotoxicity of anthracyclines in human neoplastic cells.

  2006cites this paper
• Oxidative damage and counteracting mechanisms in breast carcinoma

  2005cites this paper
• Correlation of HER2 Gene Amplification with Immunohistochemistry in Breast Cancer as Determined by a Novel Monoplex Polymerase Chain Reaction Assay

  2005cites this paper
• HER-2/neu and topoisomerase IIα gene amplification and protein expression in invasive breast carcinomas: Chromogenic in situ hybridization and immunohistochemical analyses

  2005cites this paper
• Regulation of p38 phosphorylation and topoisomerase IIalpha expression in the B-cell lymphoma line Jiyoye by CD26/dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin.

  2005cites this paper
• Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas

  2005cites this paper
• Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIα-status of the primary tumor?

  2005cites this paper
• Translating the Genome into individualized therapeutics

  2004cites this paper
• Characterization of HER2/neu and topoisomerase IIα status by FISH in locally advanced breast cancer

  2004cites this paper
• The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.

  2004cites this paper
• Topoisomerase IIα gene (TOP2A) amplification and deletion in cancer – more common than anticipated

  2003cites this paper